Farmers face an uphill battle every year, it seems—from bad weather, to weed infestations, to insect invasions. On top of this, farmers have recently had to contend with trade wars and, now, COVID-19. This year was supposed to be a moderately good year for farmers, but then COVID-19 hit, and now the agriculture industry is expecting to experience a downturn of over 20%, according to the Food and Agriculture Policy Research Institute at the University of Missouri…
Read MoreOn Friday, President Trump issued an executive order to implement what is known as the international pricing index (IPI) model for Medicare Part B drugs and biologicals. The ostensible goal of the executive order is to lower drug prices. This supposedly would be accomplished by pegging the price that the Medicare system pays for drugs to a level closer to the prices paid in a collection of other countries…
Read MorePresident Trump issued an executive order this Friday afternoon that will implement an international pricing index (IPI) model for Medicare Part B drugs and biologicals. This executive order purports to lower drug prices by linking the price paid through Medicare for drugs to prices in a number of foreign countries…
Read MoreOn Wednesday July 8, 2020, Joe Biden and Bernie Sanders “unity task force” unveiled a new health care plan that would expand Obamacare and move towards Sanders’ proposed “Medicare for all”. (1) The plan would be a detriment to the American health care systems by weakening intellectual property rights, imposing a restrictive inflationary penalty, and expanded restriction on federal funding…
Read MoreArtificially limiting America’s supply chain of raw materials for medicines and vaccines would have irrevocable effects on public health and the economy.
Read MoreAs a result of COVID-19 and mandated business shutdowns in most states, over 37 million Americans have been thrown out of work, thereby losing their health insurance benefits…
Read MoreWe cannot predict where the palliative therapies or the cure for COVID-19 will originate, but we know that the United States biopharmaceutical industry is well-positioned to help in their discovery because our country has aligned incentives to achieve the objective of providing the most innovative environment—including strong IP protections.
Read MoreThe Trump Administration is reportedly poised to issue an executive order that would affect the production of medicines, FDA-regulated emergency medical countermeasures, and active pharmaceutical ingredients. This is a terrible idea, especially during a pandemic…
Read MoreU.S. Senator Chuck Grassley (R-Iowa) is making a big push for new cosponsors of the Prescription Drug Pricing Reduction Act (PDPRA, a.k.a. the Grassley-Wyden Prescription Drug Bill), building off of President Trump’s mention of reducing prescription drug prices during his 2020 State of the Union address. Although Sen. Grassley has had trouble getting Republican Cosponsors in past, the State of the Union address has emboldened his staff to recirculate a recruitment letter, netting Sens. McSally (R-Arizona) and bringing the bill up to almost a dozen Republican cosponsors…
Read MoreThe Trump administration has been toying with the idea of implementing an international pricing index (IPI) model for Medicare Part B drugs and biologicals. The ostensible goal of the model would be to lower drug prices. This supposedly would be accomplished by pegging the price that the Medicare system pays for drugs to a level closer to the prices paid in a collection of other countries…
Read More
The Trump Administration has been toying with the idea of implementing an international pricing index (IPI) model for Medicare Part B drugs and biologicals. The ostensible goal of the model would be to lower drug prices. This supposedly would be accomplished by pegging the price that the Medicare system pays for drugs to a level closer to the prices paid in a collection of other countries…
Read MoreThe Trump Administration has been toying with the idea of implementing an international pricing index (IPI) model for Medicare Part B drugs and biologicals. The ostensible goal of the model would be to lower drug prices. This supposedly would be accomplished by pegging the price that the Medicare system pays for drugs to a level closer to the prices paid in a collection of other countries…
Read MoreOn January 16, after more than a year of negotiations with Canada and Mexico, the U.S. Senate passed the implementing bill for the U.S.-Mexico-Canada Agreement, which preserves and strengthens our economic ties with Mexico and Canada—our top two export markets—and guarantees that virtually all U.S. exports enter these markets tariff-free…
Read MoreToday, President Trump signed a partial trade agreement with China. This deal is considered Phase 1 of ongoing trade negotiations between the United States and China…
Read MoreU.S. Senator and presidential candidate Elizabeth Warren recently released a statement on her 2020 healthcare plan. She wants to allow the government to hijack the Bayh-Dole Act’s March-in provision to revoke patent protections from pharmaceutical innovators in an attempt to artificially lower drug prices…
Read MorePolicymakers and pundits from across the political spectrum are celebrating a newly unveiled plan to pass the United States – Mexico – Canada Agreement (USMCA) on trade. U.S. Trade Representative Robert Lighthizer has even called it a model for future trade agreements. The USMCA contains many improvements over its 1994 predecessor, the North American Free Trade Agreement (NAFTA) and should be passed expeditiously. Yet while there are many positive aspects to the USMCA, the agreement is far from perfect and should not be viewed as any kind of “model” for future trade agreements…
Read MoreFor months, the Trade Alliance to Promote Prosperity has written about how H.R. 3, the “Lower Drugs Costs Now” Act, would be detrimental to American healthcare and to Americans’ health…
Read MoreThe Council of Economic Advisors just came out with a new analysis of H.R. 3, the “Lower Drug Costs Now Act of 2019.”
This bill seeks to lower prices for certain drugs by forcing drug manufacturers to accept prices set by the federal government or otherwise…
Read MoreOver the Thanksgiving holiday weekend, we passed a milestone: It’s now been over one year since President Trump signed the U.S.-Mexico-Canada Agreement (USMCA) on trade—over a year! The holdup: House Speaker Nancy Pelosi…
Read MoreTime is running out for Congress to approve the USMCA, and some members of Congress are expressing frustration with the leadership. Senate Finance Committee Chairman Chuck Grassley (R-Iowa), previously optimistic about passage, has said he is now concerned about ratification of the USMCA…
Read More